Myogenes Clozapine Test promises to improve outcomes for schizophrenia patients

FHS
October 4, 2024
11:34 am

Myogenes, a leading innovator in genetic testing, has been awarded a grant from Innovate UK, the UK’s innovation agency, to further develop its revolutionary Myogenes Clozapine Test for treatment-resistant schizophrenia (TRS). This cutting-edge genetic analysis tool promises to dramatically improve patient care and generate substantial cost savings for the NHS.

The National Academy of Medicine Unveils Draft Code for Responsible AI in Healthcare

What You Should Know: – The National Academy of Medicine (NAM) is taking a pioneering step towards ensuring the ethical and safe use of Artificial

April 8, 2024

Opinion | Our Patients With Disabilities Face Unique Environmental Risks

Lowe Taylor is a physiatrist. In 2018, I was a young medical resident working on a spinal cord injury unit at the Palo Alto Veterans

September 15, 2024

Higher plant protein intake linked to lower risk of chronic kidney disease

Plant-based diets confer various health benefits, including lowering the risk of cardiovascular disease and certain cancers.

August 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.